Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MRD-guided Treatment With Pembrolizumab and Azacitidine in NPM1mut AML Patients With an Imminent Hematological Relapse

NCT03769532 is registered in ClinicalTrials.gov with Technische Universität Dresden as lead sponsor.

NCT NCT03769532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03769532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MRD-guided Treatment With Pembrolizumab and Azacitidine in NPM1mut AML Patients With an Imminent Hematological Relapse
Lead sponsor
Technische Universität Dresden
Phase
Phase 2
Overall status
Terminated
Start date
August 21, 2019
Completion date
February 13, 2025
Enrollment
26 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia